Covered recipient · General Payments record
LIBBIE S LAPP
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$2,090.21
- Reported across 120 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $348.64 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $108.73 | 6 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $82.00 | 4 |
| Lilly USA, LLC | $74.14 | 4 |
| UCB, Inc. | $40.76 | 2 |
| Amgen Inc. | $25.54 | 1 |
| GENZYME CORPORATION | $17.47 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.97 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107509597 | CMS |
| ABBVIE INC. | $20.39 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107509599 | CMS |
| ABBVIE INC. | $15.69 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107509601 | CMS |
| ABBVIE INC. | $25.27 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107509603 | CMS |
| ABBVIE INC. | $15.15 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107509605 | CMS |
| ABBVIE INC. | $15.26 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107509607 | CMS |
| Amgen Inc. | $25.54 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117606640 | CMS |
| GENZYME CORPORATION | $17.47 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139787709 | CMS |
| Lilly USA, LLC | $23.58 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135797452 | CMS |
| Lilly USA, LLC | $17.31 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135797454 | CMS |
| Lilly USA, LLC | $16.17 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135799124 | CMS |
| Lilly USA, LLC | $17.08 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135799126 | CMS |
| Novartis Pharmaceuticals Corporation | $17.94 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087086650 | CMS |
| Novartis Pharmaceuticals Corporation | $29.45 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087086652 | CMS |
| Novartis Pharmaceuticals Corporation | $13.85 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087086654 | CMS |
| Novartis Pharmaceuticals Corporation | $20.76 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087086656 | CMS |
| UCB, Inc. | $25.40 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143177437 | CMS |
| UCB, Inc. | $15.36 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143177439 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.